Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction

• Status: Terminated
• Trial end date: 2015-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare efficacy and safety of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dong-A University
• Treatments: Prasugrel Hydrochloride; Ticagrelor

Criteria

Inclusion Criteria:

• Patients with ST-segment elevation myocardial infarction

• Undergoing primary percutaneous coronary intervention

• Aged between 20 and 80 years

Exclusion Criteria:

• Previous administration of any antagonist of the platelet adenosine diphosphate (ADP) P2Y12 receptor (clopidogrel, prasugrel or ticagrelor)

• History of stroke or transient ischemic attack

• Previous gastrointestinal bleeding within 6 months, bleeding diathesis, platelet count < 100,000/mm3 or hemoglobin < 10 g/dl

• Chronic oral anticoagulation treatment

• Contraindication to the antiplatelet treatment

• Severe renal insufficiency (serum creatine>2.5 mg/dl)

• Severe hepatic dysfunction (serum liver enzyme or bilirubin>3 times normal limit)

• Sever chronic obstructive pulmonary disease (COPD) or bradycardia

• Body weight < 50 kg